Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002667-34
    Sponsor's Protocol Code Number:WA39085
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2022-01-20
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2016-002667-34
    A.3Full title of the trial
    AN OPEN-LABEL, PARALLEL-GROUP STUDY TO EVALUATE SAFETY,
    TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMIC EFFECTS OF OCRELIZUMAB IN CHILDREN AND ADOLESCENTS WITH RELAPSINGREMITTING
    MULTIPLE SCLEROSIS
    Studio in aperto, a gruppi paralleli, per valutare sicurezza, tollerabilità, farmacocinetica ed effetti farmacodinamici di ocrelizumab in bambini e adolescenti affetti da sclerosi multipla recidivante-remittente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Relapsing-Remitting Multiple Sclerosis
    Studio per valutare sicurezza, tollerabilità, farmacocinetica ed effetti farmacodinamici di ocrelizumab in bambini e adolescenti affetti da sclerosi multipla recidivante-remittente
    A.3.2Name or abbreviated title of the trial where available
    A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizum
    Studio per valutare sicurezza, tollerabilità, farmacocinetica ed effetti farmacodinamici di ocrelizu
    A.4.1Sponsor's protocol code numberWA39085
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/028/2019
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorF. HOFFMANN - LA ROCHE LTD.
    B.1.3.4CountrySwitzerland
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportF. Hoffmann - La Roche Ltd
    B.4.2CountrySwitzerland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationF. Hoffmann - La Roche Ltd
    B.5.2Functional name of contact pointTrail Information Support Line-TISL
    B.5.3 Address:
    B.5.3.1Street AddressGrenzacherstrasse 124
    B.5.3.2Town/ cityBasel
    B.5.3.3Post code4070
    B.5.3.4CountrySwitzerland
    B.5.4Telephone number000000
    B.5.5Fax number000000
    B.5.6E-mailglobal.rochegenentechtrials@roche.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Ocrevus
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration GmbH num. AIC EU/1/17/1231/001
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOcrelizumab
    D.3.2Product code [RO4964913/F07-01]
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOcrelizumab
    D.3.9.1CAS number 637334-45-3
    D.3.9.2Current sponsor codeRO4964913
    D.3.9.3Other descriptive namena
    D.3.9.4EV Substance CodeSUB121707
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typehumanized monoclonal antibody
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Relapsing-remitting multiple sclerosis (MS)
    Sclerosi multipla recidivante-remittente (SM)
    E.1.1.1Medical condition in easily understood language
    Multiple sclerosis is a disabling disease of brain and spinal cord that disrupts flow of information within brain, characterized by flare-ups with periods of remission in between (relapsing remitting)
    La MS è una malattia invalidante del cervello e del midollo spinale che interrompe il flusso di informazioni nel cervello,caratterizzata da infiammazioni con fasi di remissione(recidivante-remittente)
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10063399
    E.1.2Term Relapsing-remitting multiple sclerosis
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10039720
    E.1.2Term Sclerosis multiple
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To characterize the ocrelizumab pharmacokinetic (PK) profile in children and adolescents
    - To evaluate relationship between drug exposure and pharmacodynamic (PD) (CD19+ B-cell count) in children and adolescents
    - Caratterizzare il profilo farmacocinetico (PK) di Ocrelizumab in bambini e adolescenti
    - Valutare la relazione tra l'esposizione al farmaco e la farmacodinamica (PD) (conteggio delle cellule B CD19+) in bambini e adolescenti
    E.2.2Secondary objectives of the trial
    - To evaluate safety of ocrelizumab in children and adolescents
    - To assess anti-drug antibody (ADA) development to ocrelizumab
    - Valutare la sicurezza di Ocrelizumab in bambini e adolescenti
    -Valutare lo sviluppo di ADA contro ocrelizumab
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Able to comply with the study protocol, in the investigator's judgment
    - Age at screening between >= 10 and < 18 years
    - Body weight >= 25 kg note:enrollment of Pt with a body weight>=50kg is closed
    - Children and adolescents must have received all childhood required vaccinations as per local/national recommendations for childhood vaccination against infectious diseases calendar of immunization
    - For female patients of childbearing potential: agreement to remain abstinent or use contraception. Adherence to local requirement, if more stringent, is required
    Inclusion Criteria Related to Pediatric MS:
    - Diagnosis of relapsing-remitting multiple sclerosis (RRMS) in accordance with the International Pediatric Multiple Sclerosis Study Group (IPMSSG) criteria for pediatric MS, Version 2012, and McDonald criteria 2017
    Expanded Disability Status Scale (EDSS) at screening: 0-5.5, inclusive
    - Neurologic stability for >= 30 days prior to screening, and between screening and baseline
    - Patients naïve to prior disease-modifying therapy (DMT) or patients
    who have had less than a total of 6 months of DMT within the past 1 year
    must have one of the following:
    o At least two relapses in the last 2 years, with at least one relapse
    experienced in the previous year
    o At least two relapses in the last 2 years and >= 1 Gd-enhancing
    lesion(s) (silent or not) on T1-weighted brain MRI at any time within the
    previous year
    o At least one relapse in the previous year and >= 1 Gd-enhancing
    lesion(s) on T1-weighted brain MRI at any time within the last year
    - Patients who have had at least 6 contiguous months of DMT within the
    past 1 year must have evidence of disease activity occurring after the
    full 6-month course of treatment, that is, at least one relapse or >= 1 Gd-enhancing lesion(s) on a T1-weighted brain MRI
    - Capacità, secondo il giudizio dello sperimentatore, di attenersi al protocollo di studio.
    - Età allo screening compresa tra i >= 10 e i <18 anni
    -Peso corporeo >= 25 kg nota: nota: l'arruolamento di Pt con peso corporeo >=50kg è chiusa
    - Bambini e adolescenti devono aver ricevuto tutte le vaccinazioni obbligatorie ai sensi del calendario vaccinale locale.
    - Per le pazienti di sesso femminile in età fertile: consenso all’astinenza o all’utilizzo di contraccettivi. Se più severi, è richiesta l'osservanza dei requisiti locali.
    Criteri di inclusione correlati alla SM pediatrica:
    - Diagnosi di SMRR ai sensi dei criteri dell’International Pediatric Multiple Sclerosis Study Group (IPMSSG) per la SM pediatrica, Versione 2012, e ai criteri di McDonald del 2017
    - EDSS allo screening: 0-5,5 incluso
    - Stabilità neurologica da >= 30 giorni al momento dello screening e tra lo screening e il basale
    - I pazienti naïve a precedenti terapie modificanti la malattia (Disease-Modifying Therapy, DMT) o i pazienti che sono stati sottoposti a meno di 6 mesi totali di DMT (per es., qualsiasi IFN o GA) nell’anno precedente devono presentare una delle seguenti caratteristiche:
    1. Almeno due ricadute negli ultimi 2 anni, con almeno una ricaduta avvenuta nell’anno precedente
    2. Almeno due ricadute negli ultimi 2 anni e >= 1 lesione captante il gadolinio (Gd) (silente o meno) alle immagini di risonanza magnetica (RM) pesate in T1 in qualsiasi momento nell’anno precedente
    3. Almeno una ricaduta nell’anno precedente e >= 1 lesione captante il gadolinio alle immagini di RM cerebrale pesate in T1 in qualsiasi momento nell’ultim
    - I pazienti che hanno ricevuto un DMT per almeno 6 mesi continuativi (per es. qualsiasi interferone [IFN] o glatiramer acetato [GA]) nell’ultimo anno devono presentare evidenze di attività di malattia successive al ciclo completo di 6 mesi di trattamento, ossia almeno una ricaduta o >= 1 lesione captante il gadolinio alle immagini di RM cerebrale pesate in T1.
    E.4Principal exclusion criteria
    Excl Related to General Health:-Pregn or lactation-Known pres or suspicion of other neurol disorders that may mimic MS,includ,but not limited to,acute disseminated encephalomyelitis,andneuromyelitis optica or neuromyelitis optica spectrum disorders and any neurol,somatic or metab condit that cloud interfere with brain function or normal cognitiv or neurol develop.-Pt that are aquaporin 4 posit and myelin oligodendrocyte glycoprot(MOG)antib posit are not eligib to participate in study.-In case of ADEM-like appearance of the 1°MS attack, a 2°attack with clear MS-like feature is required.- Signif or uncontrol somatic diseases or any other signif condition that may preclude pt from participating in study-Known active bact,viral,fung,mycobacterial infect,or other infect,excluding fung infect of nail beds-Infect requiring hospit or treatm with IV anti-infectiveagents within 4 wks prior to baseline visit or oral anti-infect agents within 2 wks prior to baseline visit-History or known presence of recurrent or chronic infection(e.g.,HIV,syphilis,tuberculosis)-Receipt of a live or live-attenuated vaccine within 6 wks prior treatm allocation.Pt's vaccination record and a need forimmunization should be carefully reviewed- History or lab evidence of coagul disorders-Peripheral venous access that precludes IV administr and venous blood sampling as required per study protocol-Inability to complete an magn reson imaging(MRI)scan-Teeth braces interfering with MRI acquisition-History of cancer,including solid tumors,hemat malignancies,and carcinoma in situ(except basal cell and squamous cell carcinoma ofthe skin that have been excised and cured)-Current active alcohol or drug abuse or hist of alcohol or drug abuse.Exclus Related to Med:-Hist of a severe allergic or anaphylactic react to humanized or murine monocl antibody(mAbs)or known hypersensitivity to any component of ocreliz solution-Contraindications to or intolerance of oral or IV corticosteroids,antihistaminics,or antipyretics according to the country label-Treat with any investigational agent within 24 wks of screen or 5 half-lives,whichever is longer-Previous treatm with B-cell-targeted therapies-Any previous treatm with alemtuz, anti-CD4,cladribine,mitoxantrone,dacliz, laquinimod, total body irradiation,or bone marrow transplantation-Treatm with cyclophos, azathiop, mycophenolatemofetil,cyclospo,methotrex,or nataliz within 24 months prior to treatm alloc-Treatm with teriflun,fingolimod,or other S1P receptor modulator(e.g.,BAF312/siponimod)within 24 wks prior to treatm allocat-Treatm with fingolimod within 6 weeks prior to treatm alloc and lymphoc count<LLN for age-and sex-specif ref range treatm with any other S1P receptor modulator(e.g.BAF312/siponimod)within 24 wks prior to treatm alloc-Treatm with dimethyl fumarate within 4 wks prior to treatm alloc and lynph count <LLN for age-and sex-specific reference range-Treatm with IVIg within 12 wks prior to treatm alloc-Treatm with plasmapheresis within 4 wks prior to treatm alloc-Systemic corticost therapy within 6 wks prior to treatm alloc.Exclus Related to Lab Findings:-Posit serum beta-human chorionic growth hormone(ß-hCG)measured at screen or posit pregn test prior to first infusion of ocreliz-Posit screen tests for hepatitis B (hepat B surface antigen[HBsAg]posit, or positive hepat B core antibody[tot HBcAb]confirmed by a posit viral DNA polymerase chain reaction [PCR]) orhepatitis C antibody (HepCAb)-Posit rapid plasma reagin if confirmed by microhemagglutination assay or fluo treponemal antibody absorption test-Percentege of CD4<30%(central lab age-specif ref range %CD4: 35%-57%)-AST or ALT levels>=2.0 times the upper limit of normal(ULN)(valueas per central lab) for age- and sex-specific ref range-Levels of serum IgG 18% and IgM 8% below the LLN(value as per central lab)for age- and sex-specific ref range -Absol Neutroph Count<1.5×103/¿L-Lymph count below the LLN(value as per centr lab)forage-and sex-specif ref range
    -Grav/all-Pres.nota/sosp(sulla base di par clin o di lab)di altri disord neur che potrebb imitare la SM,compresi encefalomielite acuta diss(ADEM)e neuromielite ottica e qualsi condiz.neurol(diver dalla SM)somatica metab che potrebbe interferire con le funz cerebr o con il norm sviluppo cognit o neurolog.I paz pos all'aquaporina 4 e alla glicoprot oligodendrocitaria mielinica non possono partecip allo studio.Nel caso di comparsa simile all'ADEM del 1°attacco di SM,è necess un 2°attacco con chiare caratt simili alla SM.Ris clin o di lab alla 1°presentaz non tipici per la SM,come segni di infez o segni di encefalop,come confus,convuls,stato di coscienza ridotto.Risult anom nel liq cerebrosp alla 1°presentaz;proteina 100mg/dL;pleocitosi 50cell per mm3;pres di neutrof eosi o cell atip.Risult atip della ris magn:pres di lesioni simile all'ADEM;lesioni in posiz atip per la SM;neurite ott bilat;lesioni est del mid spin(3segm spin)-Malat somat sign o non controllate o qualsi condiz sign che potrebbe precludere la part del pz allo studio-Nota infez att di natura batt,vir,micot, micobat, ad escl delle infez micot del letto ungueale-Infez che abbia richiesto il ric in osp o il tratt. con ag antinfet per via EV nelle 4sett prec la vis basale o con ag antinfet orali nelle 2sett prec la vis basale-Pres in anamn o eviden di un’infez.ricorr o cronica-Immuniz con vacc vivo o vivo-attenuato nelle 6sett preced l’assegnaz del tratt.È pertanto necess valut il libretto delle vacc e la necess di immunizzaz del pz-Pres in anamn o evidenza negli es di lab di dist di coagul- Accesso venoso perif che precl la sommin EV e il prel di sang ven richiesti dal prot-Imposs di sottoporsi a es di RM-Apparecchio ortodont che interferisce con l’acquisiz delle immagini di RM-Pres in anamn di cancro, inclusi tumori solid, ematol e carc in situ(eccetto carc cutaneo a cell bas e squamose asport e curato)-Attuale alcol o tossicodip o storia di alcol o tossicodip.Crit di esclus correl ai med:Pres in anamn di grave reaz allerg o anafil agli antic.monocl(mAb)umanizz o murini o nota ipersens a uno qualsi dei comp della soluz di obinut-Controind o intoll a corticost somm per via orale o EV,antistam o antipir ai sensi delle indicaz approvate localm-Tratt con ag sperim nelle 24sett o 5emivite del farmaco prec lo screen,qualque sia il periodo+lungo-Prec tratt con ter mirate alle cell B-Qualsi prec tratt con alemtuz,antiCD4,cladribina,mitoxantrone,dacliz,laquinimod,azatioprina,micofenolato mofetil, ciclosp,metotress o nataliz nei 24mesi prec all'assegn del tratt-Tratt con teriflunomide o mod del rec S1P nelle 24sett preced.all'assegn del tratt-Tratt.con fingolimod entro 6sett prima dell'assegn del tratt e conta dei linfo<lim inf della norma(LLN)(lim inf alla norma)per l'interv di rif spec per età e sesso.tratt con qualsi altro mod di rec S1P(ad es BAF312/siponimod)entro 24sett prima dell'assegnaz del tratt-Tratt con dimetilfumarato nelle 4sett prec l'assegn del tratt e conta dei linfo<LLN per l'interv di rif spec per età e sesso-Tratt.con IVIg nelle 12sett prec l’assegn del tratt-Tratt.con plasmaferesi nelle 4sett prec l’assegnaz del tratt-Terap con corticost sist nelle 6sett prec l’assegn del tratt.Periodo di screen.potrebbe essere esteso(senza però superare 10sett)nei paz.che hanno utilizzato corticost sist per la SM prima dell’assegnaz del tratt-Crit di esclus.correl ai ris di lab:-Pos dell’orm ß-hCG nel siero,allo screen,o test di grav pos prima della prima inf di ocreliz-Test di screen pos per epatB(HBsAg pos,o HBcAb tot pos,confermato da test PCR sul DNA vir)o per l’epatC(HepCAb)-Reagina plasm rapida pos,se confermata da test di microemoagglutinaz o test di assorb di antic anti-treponema fluor-% di cell CD4<30%(interv di rif del lab centr spec per l’età per %CD4:35%-57%)-Liv di AST o ALT>=2,0 volte il lim sup della norma(ULN)sec l’interv di rif.spec per età e sesso-Liv sier di IgG 18% e IgM 8% inf al lim(LLN)(valore sec il lab.cent)sec l’interv di rif spec per età e sesso-
    E.5 End points
    E.5.1Primary end point(s)
    1. Serum concentration of ocrelizumab
    2. Levels of CD19+ B-cell count in blood
    1. Concentrazioni sieriche di ocrelizumab a tempistiche prestabilite
    2. Livelli delle cellule B CD19+ nel sangue
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 to 6 mounths
    1 - 6 mesi
    E.5.2Secondary end point(s)
    1. Occurrence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v54.0
    2. Change from baseline in vital signs
    3. Change from baseline in clinical laboratory test results
    4. Level of circulating B cells, T cells, natural killer cells, and other
    leukocytes
    5. Developmental milestones (e.g., growth, bone age, age at menarche, Tanner staging)
    6. Non-MS CNS pathology as measured by brain MRI scans
    7. Levels of blood immunoglobulins
    8. Antibody titers against standard vaccines
    9. Presence of ADAs during the study relative to the presence of ADAs at baseline
    1. Comparsa e severità degli eventi avversi, determinandone la severità in base ai criteri NCI CTCAE v. 4.0 2. Variazione dei parametri vitali rispetto al basale 3. Variazione dei risultati delle analisi cliniche di laboratorio rispetto al basale 4. Livelli di cellule B, cellule T, cellule natural killer e altri leucociti in circolo 5. Tappe fondamentali dello sviluppo (p. es., crescita, età ossea, età al menarca, stadiazione di Tanner) 6. Patologia del SNC diversa dalla SM rilevata mediante RM cerebrale 7. Livelli di immunoglobuline nel sangue 8. Titoli degli anticorpi contro i vaccini standard 9. Presenza di ADA nel corso dello studio rispetto alla presenza di ADA al basale
    E.5.2.1Timepoint(s) of evaluation of this end point
    up to 48 weeks
    fino a 48 settimane
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity and Exploratory
    Immunogenitcità e parametri esplorativi
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    open, parallel group
    in aperto , con gruppi paralleli
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Italy
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of study is defined as either the last patient, last visit (LPLV) of the study or the LPLV in the SFU period or B-cell monitoring period of the SFU period, whichever is later, or when the Sponsor decides to discontinue the study or development program in pediatric MS.
    La conclusione dello studio coinciderà con l’ultima visita dell’ultimo paziente (Last Patient, Last Visit, LPLV) dello studio o con la LPLV del periodo SFU o della fase di monitoraggio delle cellule B del periodo SFU, a seconda di quella che avverrà più tardi, o quando lo sponsor deciderà di interrompere lo studio o il programma di sviluppo nella SM pediatrica.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 12
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 24
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Informed consent for study participation signed by the parents or a legal guardian, with patient assent obtained verbally and when possible, in writing, from all pediatric patients old enough to fully comprehend the assent document
    il Modulo di consenso informato per la partecipazione allo studio viene firmato dai genitori o dal tutore legale, con l'assenso del paziente ottenuto verbalmente e, quando possibile, in forma scritta da tutti i pazienti pediatrici grandi abbastanza d
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state6
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 6
    F.4.2.2In the whole clinical trial 36
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Currently, the Sponsor does not have any plans to provide Sponsor study drug or any other study treatments or interventions to patients who have completed the study. The Sponsor may evaluate whether to
    continue providing ocrelizumab in accordance with the Roche Global Policy on Continued Access to Investigational Medicinal Product, available at the following Web site: http://www.roche.com/policy_continued_access_to_investigational_
    Al momento lo Sponsor non prevede di fornire il farmaco (ocrelizumab)o altri trattamenti in studio ai pazienti che hanno completato lo studio. Lo Sponsor può valutare se continuare a fornire Ocrelizumab in accordo con la politica globale di Roche sull'accesso continuo all'IMP, disponibile sul seguente sito Web: http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-09-03
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-07-18
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 12:17:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA